ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.

Dr Milind Desai  (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene replacement therapy, in adults with Mybpc3-associated hypertrophic cardiomyopathy (NCT05836259; Tenaya Therapeutics). The primary outcome measures of MyPEAK-1 were the number and severity of adverse events over the course of the study and the number of serious adverse events related to the study drug.

Key findings in the first three patients showed the treatment was feasible, and safe.

Interview Questions:

1. What is Mybpc3-associated HCM and what is the prevalence?
2. What are the current unmet needs in managing Mybpc3-associated hypertrophic cardiomyopathy, and why is this trial important?
3. Could you tell us about the mechanism of action behind Tn-201?
4. What was the study design and patient population?
5. What were the key findings, and were there any surprising results?
6. How should these findings impact clinical practice?
7. What further study is needed in this area?

Recorded on-site at ACC in Chicago, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.